

# Regional smertesamling 2019,

29.11-2019. Store Aud, Ullevål

Regional Kompetansetjeneste for Smerte -ReKS


## Smerte hos eldre er vanlig og vanskelig -- lærerrike pasienthistorier 12.45-13.15

Harald Breivik

Nå forfremmet til Sjuende far i Bygg 37B

Eldrebølgen er her

# Aftenposten 27.06-2018



Eldreboøgen er her og følges av en  
**tsunami**

Eldreølgen er her og følges av en  
**tsunami**

..en **tsunami** av eldre som trenger behandling for **smerter**


Arthur Schopenhauer (1788 - 1860)

Pessimismens filosof:

**“Å leve er å lide”**

## Kronisk smerte i prosent av befolkningen

Intervju av **3373** hjemmeboende personer i **alder 16-95 år**



**Enkene lever og lider!**

Gjennomsnitt for alle over 18 år  
= **29,3%**

Nielsen CS, Folkehelse rapporten 2010, kapt16.

**Figur 1.** Forekomsten av kroniske smerter i prosent av befolkningen etter alder og kjønn.

Kilde: Data fra Levekårsundersøkelsen 2005. Analysen er basert på besvarelse fra 3371 hjemmeboende personer i alder fra 16–95 år. Data for barn 6–15 år er rapportert av deres foreldre. Kroniske smerter er definert som smerter med varighet på seks måneder eller mer.

# Hvorfor **lider** eldre av mer smerter enn yngre?

Smerte er oftere et symptom på en (eller flere) sykdommer hos eldre – f.eks.: Artrose;diabetes, **cancer-survivors**.




**Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health**

Andrew M. Briggs, BSc(Physio)Hons, PhD,<sup>1,2</sup> Marita J. Cross, BSc (Hons), MPH (Hons), PhD,<sup>2</sup> Damian G. Hoy, BAppSc(Physio), MPH, PhD,<sup>4,5</sup> Lidia Sánchez-Riera, MD, PhD,<sup>6</sup> Fiona M. Blyth, BSc (Med), MBBS (Hons), MPH, PhD, FAFPHM,<sup>7</sup> Anthony D. Woolf, BSc, MBBS, FRCP<sup>8</sup> and Lyn March, MBBS, MSc, PhD, FAFPHM, FRACP<sup>9</sup>

**Table 3.** Global Prevalence (%) (Lower, Upper 95% Uncertainty Intervals) of Activity-Limiting Low Back Pain and Neck Pain That Had Lasted for At Least 1 Day, Knee Osteoarthritis, Hip Osteoarthritis, Rheumatoid Arthritis, and Other Musculoskeletal Conditions, by Age Group

Age group	Low back pain	Neck pain	Knee osteoarthritis	Hip osteoarthritis	Rheumatoid arthritis	Other musculoskeletal conditions
All ages	9.4 (9.0, 9.8)	4.9 (4.6, 5.3)	3.7 (3.5, 4.0)	0.9 (0.7, 1.0)	0.24 (0.23, 0.25)	8.2 (8.0, 8.5)
55–64 years	16.9 (16.0, 17.9)	8.2 (7.6, 8.8)	13.1 (12.3, 14.0)	2.8 (2.4, 3.3)	0.53 (0.51, 0.55)	16.5 (16.0, 17.2)
65–74 years	20.0 (19.0, 21.1)	8.0 (7.5, 8.6)	14.2 (13.4, 15.2)	4.1 (3.6, 4.9)	0.78 (0.75, 0.82)	22.4 (21.4, 23.4)
75–84 years	22.9 (21.8, 24.2)	7.8 (7.2, 8.4)	14.9 (14.1, 15.9)	5.8 (5.1, 6.9)	1.06 (1.01, 1.11)	24.8 (23.7, 26.0)
85+ years	23.3 (22.3, 24.6)	7.3 (6.8, 7.8)	15.4 (14.5, 16.4)	7.9 (6.9, 9.3)	1.35 (1.28, 1.43)	24.9 (23.7, 26.3)



**Figure 1. Changing Demographic Characteristics of Cancer Survivors in the United States.**

Shown is the number of cancer survivors according to age group, starting

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

## Cancer Survivorship

Charles L. Shapiro, M.D.

**A**DVANCES IN CANCER SCREENING AND EARLY DETECTION, IMPROVEMENTS in therapeutics, and supportive care all contribute to decreasing cancer mortality. Figure 1 shows the changing demographic characteristics of the

Bedre screening, tidlig diagnose, bedre kurativ terapi, bedre oppfølging

→ Flere overlever som **kurerte kreft-pasienter – cancer-survivors**

→ Cytostatika, stråler, kirurgi → **nerveskadesmerter**

→ Bio-**psyko-sosiale** komponenter **ofte betydelige**

i cancer-survivors med smerter

From the Icahn School of Medicine at Mount Sinai Uptown, New York. Address reprint requests to Dr. Shapiro at the Icahn School of Medicine, 1 Gustave L. Levy Pl., Box 1079, New York, NY 10029, or at [charles.shapiro@mssm.edu](mailto:charles.shapiro@mssm.edu).

N Engl J Med 2018;379:2438-50.

DOI: 10.1056/NEJMra1712502

Copyright © 2018 Massachusetts Medical Society.

WHO: “Numbers and proportion of elderly increase globally & rapidly”

WHO, Geneva, 2015:

«The proportion of those **above 65 years** is soon larger than those 5 years and younger »

**Pain** is often part of the diseases of the elderly....

**Burden** of diseases is much aggravated **by pain**..

**Aging in good health** is **NOT** the rule....

**Advice from WHO (2015) to secure healthy aging...**

## WHO(2015):Healthy aging – what can we **all** do?

- Skaff deg en god utdanning
- Ikke røke tobakk
- Bruk svært lite alkohol
- Sunn livsstil senest fra 30-års alder
- Behandle høgt blodtrykk allerede i “middle age”
- Diet med fisk og grønnsaker (“Mediterranean diet”)
- **Vær fysisk aktiv, mentalt aktiv, og sosialt aktiv**
- Høre-apparat er viktig
- **Hold din partner sunn og glad.**

Så noen lærerike pasienthistorier

En **frisk** cancer-coli survivor (10 år etter operasjon), nå 72-år:

Hun venter på kirurgi for humerus-fractur **etter fall**.

**Sterke akutte smerter** (**10/10** ved bevegelse; **7/10** i ro)

Forslag til smerte-lindring?

Diclofenak (=det globalt mest brukte NSAID(=voltaren))

**Diklofenak** til en **frisk** cancer-survivor **72 år**

Hun venter på kirurgi for humerus-fractur etter **fall**

Diclofenak 50 mg tbl x3 dgl → lindret **smerte i ro-2/10**

Smerte ved **bevegelse** fortsatt sterke (**7-8/10**)

Etter 4-5 dager føler hun seg veldig uvel og svimmel,

**Ingen andre symptom!**

Hva kan dette være?



Diclofenak (=det globalt mest brukte NSAID(=voltaren))

**Diclofenak** til en **frisk** cancer-survivor **72 år**

Hun venter på kirurgi for humerus-fractur etter **fall**

Diclofenak 50 mg tbl x3 dgl → lindret **smerte i ro-2/10**

Smerte ved **bevegelse** fortsatt sterke (**8-9/10**)

Etter 4-5 dager føler hun seg veldig uvel og svimmel,

**Ingen andre symptom!**

Hva kan dette være?

Men så....

Tilfeldig oppdaget: **Svart avføring.**

Hgb fra 15 g/dL til 7 g/dL

**Gastroscopi: Blødende ulcus.**

**OBS: INGEN** ulcus smerter

# **Flere** problem med NSAID til eldre?

**NSAID** (diclofenak, ibuprofen, naproxen,++) er effektive til akutt-smerte lindring hos elder, men **risiko-fylte**

**NSAID** gir gastrointestinale **ulcus uten ulcus-smerter**

**NSAID** hemmer **blodplatene** og **øker blødning-risiko**

**NSAID øker risiko** for **slag, infarkt, nyresvikt**

**NSAIDs skal IKKE forskrives til eldre (over 65 + år) for kroniske smerter**

**Gir:**

**Smertefrie GI-sår → blødning**

**Cardiovaskulære katastrofer (MI/Slag)**

**Forverrer allerede redusert nyrefunksjon**

**Gjelder:**

**Ibuprofen, naproksen, ketoprofen, diklofenak, ketorolak, piroksikam, meloksikam**

**Celekoksib og etorikosib (Arcoxia) har samme effekt på nyrer og cardiovaskulære system**

# Risiko for **cardiovaskulære** komplikasjoner **øker** med **dosen** og med **varigheten** av behandlingen med NSAIDs/ COXibs

Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM.

“Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of (almost **450 000**) individual patient data”.

BMJ 2017;357:j1909.

“With use for one to seven days the probability of myocardial infarction **risk** was increased for **celecoxib**, for **ibuprofen**, and **highest for diclofenac, naproxen, and rofecoxib**”

Risk of myocardial infarction increased with time up to one month.

Risk of myocardial infarction increased with dose.

Take-home message:

- (1) Risk of myocardial infarction increases **from first dose** of traditional NSAIDs and COX-2 inhibitors.
- (2) No practical difference in risk between traditional NSAIDs and the more COX-2 selective inhibitors.
- (3) Do not prescribe NSAIDs to patients who already have cardiovascular risk-factors**

# NSAIDs\* must be used with caution in:

- Age > 65 years (renal impairment)
- Diabetes (renal impairment)
- Widespread vascular disease
- Patients on **ACE-inhibitors, diuretics**, betablockers, cyclosporin, methotrexate
- Major surgery (risk of decreased renal function)

(Rowbotham et al: Royal College of Anaesthetists - 1998)

**\* (also COX2-inhibitors)**

Åndsfrisk 86 år: 12 år etter ca coli(coecum-nær) og 8 år etter operasjon for ca coli sigmoideum – nå **akutt lumbago** (NRS 5-7/10)

Han har nå moderat **hjertesvikt** med bevart ejeksjons-fraksjon og **nyresvikt** (eGFR<sub>cystatinC</sub> 22ml/min/1.74m<sup>2</sup>)

**Behandles med ACE-hemmer: Ramipril 1,25 mg x 2, Burinex 1 mg x 2.**

Han prøver paracetamol 1 g → litt/lite smertelindring

Får beskjed om å ta Ibux 400 mg x 3 i tillegg

→ 2 dager etter: **Uttalt ankel-legg-ødem.....**

**Hva nå??**

# Fordeler med **steroider** for lindring av akutte smerter

- Rask og lengevarende analgesi
- Antiemetisk
- Ingen blødning
- Ingen effekt på nyrene/lever
- Ikke økt risiko for sårinfeksjon
- Ikke allergi

Romundstad, L et al. Acta Anaesth Scand (2004)

Romundstad et al. Anesth Analg (2006)


# NSAIDs and “Triple whammy” acute renal failure

Complex interplay among the effects of

1. NSAIDs,
2. Angiotensin-converting enzyme inhibitors (ACE) or angiotensin receptor antagonists (ARA),
3. and diuretics



# Age-dependent renal impairment not well estimated from serum creatinine



**Rate of decline:**

**1 mL/min per year of life  
after the 40<sup>th</sup> year of age**

**“Creatinine-blind  
range”**

# NSAIDs and **Triple whammy** acute renal failure

Kollinius-Bringland M, Affas F, Wretenberg P. Acute renal failure after local infiltration anesthesia. Two cases related to orthopedic surgery described. *Lakar-tidningen* 2013;110:284-5.

Prieto-García L, Pericacho M, Sancho-Martínez SM, Sánchez Á, Martínez-Salgado C, López-Novoa JM, López-Hernández FJ. Mechanisms of triple whammy acute kidney injury. *Pharmacol Ther* 2016, <http://dx.doi.org/10.1016/j.pharmthera.2016.07.011>. Aug 1. [Epub ahead of print]. pii: S0163-7258(16)30136-X.

NSAIDs should **not** be prescribed for elderly (>65 + years)  
for **chronic pain**

Occasional, short term use for acute pain may be **OK?**

Never more than **3 (- 5) days?**

# “NSAIDs bring on cardiac diseases in osteoarthritis patients”

- **NSAID use for osteoarthritis may bring on cardiovascular disease**
- Published: Aug. 7, 2019 at 12:51 PM

Tauren Dyson

Aug. 7 (UPI) -- Nonsteroidal anti-inflammatory drugs that treat inflammation and pain raise the risk of congenital heart disease, heart attack and other conditions for people with osteoarthritis, new findings show.

- In fact, people with osteoarthritis who take NSAIDs have a 23 percent higher likelihood of developing cardiac disease compared to people without the condition, according to a [study published](#) in August in Arthritis Rheumatology.
- In addition, they have a 42 percent higher risk of developing congestive heart failure, 17 percent of ischemic heart disease and 14 percent risk of stroke.
- "To the best of our knowledge, this is the first longitudinal study to evaluate the mediating role of NSAID use in the relationship between osteoarthritis and cardiovascular disease in a large population-based sample," senior study author Aslam Anis, a researcher at the University of British Columbia and study senior author, said in a news release.
- For this longitudinal study, the researchers examined data for 7,743 osteoarthritis patients from British Columbia, Canada, comparing them with 23,229 people who did not have osteoarthritis. They found about 41 percent of the cardiovascular risk within this group came from NSAID use.
- "Our results indicate that osteoarthritis is an independent risk factor for cardiovascular disease and suggest a substantial proportion of the increased risk is due to the use of NSAIDs," Anis said. "This is highly relevant because NSAIDs are some of the most commonly used drugs to manage pain in patients with osteoarthritis. It's important for people with OA to talk to their care providers and discuss the risks and benefits of NSAIDs."

# Uheldige—farlige komplikasjoner til NSAIDs (COX-1 og/eller COX-2 hemmere)

**COX-1** hemmere (ibuprofen, naproxen, diklofenak, piroksikam; ketorolak (bare til intravenøs i Norge))

Hemmer produksjon av **pro**-inflammatoriske prostaglandiner, spesielt **thromboxane A**

(1) COX-1 hemming gir den **NonSteroide Antiinflammatoriske Droge (NSAID)** - effekten

(2) Hemmer blodplate-aggregasjon

→ **plate-proppen** dannes ikke

→ **Øket** risiko for **blødning**

**COX-2** hemmere (celekoksib, etorikoksib, parekoksib (bare til intravenøs))

Hemmer produksjonen av **anti**-inflammatoriske prostaglandiner, spesielt **prostacyclin** som fører til

→ **hypertensjon, nyresvikt;**

→ **aterosklerotiske plaque vokser** → **myocard-infarkt; → plutselig hjerte-død**

**cerebrale infarkt → slag**

Ingen øket blødningsrisiko

# NSAIDs kan hemme **både** COX-1 og COX-2

Ketorolak har nesten bare COX-1 hemming

Etorikoksib har nesten bare COX-2 hemming

De øvrige har både COX-1 og COX-2 i ulike fraksjoner

Diklofenak og meloksikam hemmer COX-2 **mer** enn COX-1

De cardiovaskulære komplikasjoner like uttalte for diklofenak, ibuprofen og naproksen som for celekoksib.

Pasienter med cardiovaskulære sykdommer bør

**ikke** bruke **tradisjonelle NSAIDs**, heller **ikke Arcoxia** (etorikoksib) for smertelindring.

Bruk **paracetamol**, evt med kodein

Mann 76 år-- kommer til sin tannlege med sterke smerter i h. overkjeve – opp til pannen

Ingen endringer i munnslimhinne, tannkjøtt, rtg av tanngarden—

Kan hende litt rødmusset høgre kinn?

Hva er dette?

Primær orofacial smerte?

4 uker senere - hva er dette?

Fra Wikipedia





Akutt herpes zoster i n.trig V1  
og V2



Fra Wikipedia

# Akutt herpes zoster

# Akutt HZ og Postherpes-nevralgi

Ved tilfeldig immunforsvar svekkelse → Reaktivering av varicella-zoster virus (VZV) etter vannkopper (varicella) som barn.

Reaktiverede VZV i dorsale ganglier → akutt herpes zoster (HZ) omlag **1-4 av 100** eldre personer hvert år

**Livslang postherpes nevralgi etter akutt HZ i ca. 20%**

# En 76 år, tidligere frisk, mann med HZ

Akutt HZ, V1 + V2; voldsomme smerter **8-10/10**

➤ innlagt kommunal akutt overvåkingsavdeling

➤ fikk aciklovir (Tbl. Zovirax 800 mg x 5 dgl)

➤ og **amitriptylin (Sarotex)** 25 mg dgl,

➤ Pforte+Ibux hjalp bare litt (ansvarlig lege ikke tilgjengelig!).

➤ Skrev seg ut pga u-utholdelige smerter:

➤ Fikk hjelp av fast(?) -lege: **OxyContin 10 mg x 3** (++) dgl

➤ **Obstipasjon! Urinretensjon! → Urosepsis**

➤ → Intensivavdeling: Diverse komplikasjoner.

**Overlevde, men med post-herpes nevralgi**



# Hva kunne vært gjort bedre?

**Forebygge med vaksine mot herpes zoster!**

**Forebygge opioid-obstipasjon (Movendig/Targiniq)!**

**Eldre menn har risiko for urinretensjon av opioid!**

**Ikke forskriv amitriptylin (Sarotex) →svimmel/sedert+fall-risiko**

Amitriptylin (Sarotex) skal **IKKE** forskrives  
til eldre (over 65 + år)

→ trett, ortostase, svimmel → fare for  
→ **fall**

# Varicella-Zosta Virus (VZV)-vaksine (**Zostavax**) til alle over 60-år?

**Zostavax (levende, svekket virus) vaksinasjon**  
reduserer insidensen av akutt HZ med over 50%  
og postherpes nevralgi med mer enn 60%

In **Scotland** HZ-vaccine (Zostavax) is **offered free**  
and persons >60 y are urged to accept the vaccine,  
→ Health care system saves a large amount compared with a  
unvaccinated population

## New Herpes Zoster vaccine (**Shingrix**) should be offered to elderly adults

Neuzil KM, Griffin MR. **Preventing Shingles and Its Complications in Older Persons**  
(Editorial) N ENGL J MED 2016;375:1079-80.

A.L. Cunningham et al. Efficacy of the Herpes Zoster **Subunit Vaccine** in Adults, 70 Years of Age or Older. NEJM 2016;376:1019 (**Shingrix**)

Persons > 50 years: 97% protection against acute HZ

Persons > 70 years: **91% protection** against acute HZ

(n=139 009)

**88% protection** against postherpetic neuralgic pain among the few who did have acute HZ.

(I Norge: Må søke om registrerings-fritak)

# Bare få utvalgte med innsikt og god økonomi tar HZ-vaksine i Norge

- Ingen regner med å få HZ
- men opp til 4% (økende med alder) får HZ
- HZ-vaksine lite kjent
- HZ-vaksine er dyr (Shingrix er 2500 NOK x 2)

(Kjenner bare 4 personer som er vaksinert)



# 68 years man with chronic low back pain

His GP prescribed paracetamol and tramadol

**Tramadol** dose gradually increased to 500(++?)mg daily

Pain as before, complained of severe constipation,  
not sleeping well, dysphoric/anxious, poor memory.

Tramadol was tapered and discontinued after 6 months  
(+clonidine 25 mcg x 1-3d- but dizzy!):

**Back-pain as before.**

Feeling better, socially active, libido returned.

**“I have my head back and my wife has her husband back”**

# Opioid-abstinens og Antidepressiva-abstinens når tramadol seponeres

## Opioid-abstinens

- Motorisk urolig/myocloner rykninger
- Akathisia
- Engstelig, panikk
- Nedstemt
- Søvnproblem
- Svette-hyperhidrose
- Nese drypp, tåreflod
- Diare, mageknip
- Kvalme
- Mydriasis

## Antidepressiva-abstinens

- “Rest leg syndrom”
- Parestesier
- Engstelig
- Panikk-angst
- Forvirring
- Delusions/Hallusinasjoner
- Paranoia



# NEWS

---

## NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms

Gareth Iacobucci

The BMJ

The National Institute for Health and Care Excellence has amended its guidelines<sup>1</sup> on depression to recognise the severity and length of antidepressant withdrawal symptoms.

press ahead with withdrawal services and a helpline for those who have become dependent on these and other prescribed drugs.”

# Hovedproblem ved medikamentell behandling av eldre med smerter

## Smalt terapeutisk vindu av

- analgetika (morfin/kodein/oksykodon) og
- antihiperalgetika (amitriptylin!, gabapentin)

**Smertelindring begrenses av** bivirkninger som sedasjon og svimmelhet → farlig hos eldre

→ snubler i gulvteppe → fallskader,

typisk er collum-fractur

(en katastrofe → “begynnelsen på slutten”)

# Hvorfor er smertebehandling vanskeligere hos eldre ?

Egentlig samme prinsipp som for yngre voksne, men co-morbiditeter og polyfarmaci til disse gjør farmakologisk behandling “krevende”

Noen vanlige problem:

1. **Alder-relaterte nyre-problem** hos alle eldre og gamle  
→ akumulering av medikament som skilles ut renalt: pregabalin (Lyrica)
2. **Efflux-transporteren, Permeability-Para-glycoprotein (Pgp)** i BBB er mindre effektiv hos eldre og særlig hos gamle
3. → **Perifert active droger slipper inn i CNS, e.g. naloxegol, loperamide**
4. **Multiple medikament-interaksjoner**, noen velkjente og mange vi ikke var klar over (pga for lite kunnskap!)

## Flere eksempler:

PPIgruppen (lansoprazol) øker Moventig (naloxegol) inne i CNS og utløser opioid-abstinens

Imodium (loperamide – et potent opioid) slipper gjennom BBB hos eldre og gir typiske subjektive morfin-effekter

**Ukjent for mange at NSAID-interaksjoner kan gi akutt nyresvikt: “Triple-whammy acute renal failure”**

Complex interplay among the effects of

1. NSAIDs,
2. Angiotensin-converting enzyme inhibitors (ACEIs),  
angiotensin receptor antagonists (ARAs),
3. and diuretics

# Enda ett lærerikt tilfelle av feilbehandlet kronisk smerte hos en **eldre kvinne**

og et eksempel på en økende gruppe pasienter til Avd for smertebehandling, OUS:

**Rydde opp i feilbehandla smertepasienter.....**

# 75yo rullestol-bundet lady med uttalte ryggsmarter og neuropatisk legg-smarter

## Medisinering:

- Transdermal fentanyl 100 µg/h (=720 mg oral morphine/24 h)
- Diclofenac (Voltaren) 150 mg daily.
- Pregabalin (Lyrica) 450 mg/daily
- PPI (lanzoprazol) 60 mg/daily
- Amitriptylin 50 mg
- Acetylsalicylic acid 75 mg/daily
- Atorvastatin (Lipitor)40 mg/daily
- Bumetanid (Burinex) 1 mg/daily

## ➤ **To store problem:**

1. Uttalt opioid-indusert mage- og tarm-dysfunksjon(OiBD) med uttalt **cardialgi** og **obstipasjon** (PPI & laxatives -ineffective)
2. **Uttalt sedation, sover** ("nodding")mesteparten av 24 hrs, og **sosialt isolert**.



## Behandling av hennes OiBD - obstipasjon og cardialgi:

Forskrevet **naloxegol** –(Moventig)

som er en **perifert aktiv my-opioid receptor antagonist** (PAMORA):

Advart om at hun måtte være i nærheten av do når hun tok første Moventig (naloxegol) tablett på 25 mg.

→ Hun hadde en “voldsom” **tarm-tømming** (not all in WC)

**Men,**

Hun fikk også uttalt **opioid-abstinens** symptom, og mer smerte:

**Hvordan kan det forklares?**

# Why is naloxegol a PAMORA?

Naloxegol is a PEGylated **naloxone** molecule where a polyethylene-glycol moiety is attached to make a **very large molecule** that should ensure that it does not get into the brain.

Not a good explanation.....

# Permeability glycoprotein= Pgp

is an **efflux transporter** – transports “**toxins**” out of cells against concentration gradients

A protein of the [cell membrane](#) that pumps toxins out of cells. It is a defence mechanism against harmful substances.

Pgp is extensively distributed and expressed:

- **in the [capillary endothelial cells of the blood-brain barrier](#) where it pumps “toxins” out of CNS back into the capillaries.**
- in the [intestinal epithelium](#) where it pumps [xenobiotics](#) (such as toxins or drugs) back into the intestinal [lumen](#),
- in [liver cells](#) where it pumps them into [bile ducts](#),
- in the cells of the [proximal tubule of the kidney](#) where it pumps them into urine-conducting ducts,

# P-glycoprotein = Permeability glycoprotein = P<sub>gp</sub> = Multidrug resistance protein 1 (MDR1)

An important protein of the [cell membrane](#) that pumps many foreign substances out of cells.

It is an [ATP](#)-dependent [efflux pump](#) with broad [substrate](#) specificity.

It exists in animals, fungi and bacteria and likely evolved as a defence mechanism against harmful substances.

Pgp is extensively distributed and expressed:

- in the [intestinal epithelium](#) where it pumps [xenobiotics](#) (such as toxins or drugs) back into the intestinal [lumen](#),
- in [liver cells](#) where it pumps them into [bile ducts](#),
- in the cells of the [proximal tubule of the kidney](#) where it pumps them into urine-conducting ducts,
- **in the [capillary endothelial cells](#) composing the [blood-brain barrier](#) where it pumps “toxins” back into the capillaries.**

# Why is naloxegol a PAMORA?

Naloxegol is a substrate for Permeabilityglycoprotein-(P<sub>gp</sub>)

- P<sub>gp</sub> keeps naloxegol outside the BBB


## Some reasons P<sub>gp</sub> is not able to keep naloxegol outside the BBB

- P<sub>gp</sub> is reduced in **elderly** persons
- **Renal** failure down-regulates P<sub>gp</sub>
- Co-medications may be **inhibitors** of P<sub>gp</sub>

## **Elderly patients with reduced renal function:**

Not enough P<sub>gp</sub> to keep all naloxegol molecules outside the BBB – the Blood Brain Barrier

# Age-dependent renal impairment not well estimated from serum creatinine



Rate of decline:

1 mL/min per year of life  
after the 40<sup>th</sup> year of age

“Creatinine-blind  
range”

# Common pharmacological inhibitors of Permeability-glycoprotein (P<sub>gp</sub>)

lansoprazole, omeprazole and other proton-pump inhibitors

amiodarone, azithromycin, captopril,

clarithromycin, cyclosporin, colchicine, diltiazem, erythromycin, felodipine,

nifedipine, paroxetine, piperine,

quercetin, quinidine, quinine, reserpine, ritonavir, sertraline, tariquidar, tamoxifen and verapamil.

**(Imodium** (loperamide) and quinidine → strong opioid-agonist effect in the CNS)

Solhaug V, Molden E. Individual variability in clinical effect and tolerability of opioid analgesics. Importance of drug interactions and pharmacogenetics. **Scand J Pain** 2017

# Was she taking any inhibitors of P<sub>gp</sub>'s pumping of naloxegol to outside of BBB?

- Fentanyl patch 100 µg/h
- Pregabalin (Lyrica) 450 mg/daily
- Diclofenac (Voltaren) 150 mg daily (for several years)
- **Lanzoprazol** 60 mg/daily
- Burinex (bumetanid) 1 mg for leg-oedema
- Atorvastatin (Lipitor) 40 mg/daily
- Acetylsalicylic acid 75 mg/daily

## Several problems with her co-medications!

- **Renal failure** (?caused by diclofenac 150 mg/d for years)  
**But:** her eGFR<sub>creatinine</sub> = 58 ml/min/1.73m<sup>2</sup>



This 75 yrs wheelchair-bound lady had a low muscle mass – and creatinine was not an appropriate measurement for kidney function

**Renal failure** (aggravated by diclofenac 150 mg/d for years)

eGFR<sub>creatinine</sub> = 58 ml/min/1.73m<sup>2</sup>

eGFR<sub>cystatin C</sub> = **32** ml/min/1.73m<sup>2</sup>

# Cystatin C estimate of GFR in elderly:

[www.egfr.se](http://www.egfr.se)

**Cystatin C** is a peptide from all nucleated cells. The **muscle-mass independent cystatin C** serum concentrations for estimating renal function in **children and frail elderly patients** developed by Anders Grub, University of Lund, Sweden.

See [www.egfr.se](http://www.egfr.se)

**Lyrica 450 mg/day and renal impairment caused the extreme sedation in this 75 y patient**

**Diclofenac 150 mg/d** taken for several years contributed to her severe renal impairment.

**Lyrica was reduced to 150 mg/day**, serum concentration of pregabalin reduced from **75** to **15** micromol/L

and she **“woke up”**

**Buprenorphine** not excreted by the kidneys  
and causes less endocrine disturbances

Converted to **transmucosal buprenorphine**

**Temgesic** sublingual tablets 0.4 mg, 2 x 4 = 3.2 mg/day

She is now **awake** with good **pain relief** and less **OiBD**

According to **CDC** (Centers for Disease Control and Prevention, Atlanta, GA, USA, March 2014 (email: Mbohm @cdc.gov)

3.2 mg buprenorphine sublingual = 32%/90% mg morphine orally → with better effect on her back-pain.

**Buprenorphine** has less effect on **androgen** hormone

# Was she taking any inhibitors of P<sub>gp</sub>'s pumping of naloxegol to outside of BBB?

- Fentanyl patch 100 µg/h
- Pregabalin 450 mg/daily
- Diclofenac (Voltaren) 150 mg ddaily
- **Lanzoprazol** 60 mg/dayly
- Burinex (bumetanid) 1 mg for leg-oedema?
  
- **Renal failure** (aggravated by diclofenac 150 mg/d for years)  
eGFR creatinine = 58 ml/min/1.73m<sup>2</sup>  
eGFR cystatin C = 32 ml/min/1.73m<sup>2</sup>

**Several problems with her co-medications!**

# She had been on several drugs that caused adverse effects

Fentanyl transcutaneous patch 100  $\mu\text{g}/\text{h}$  (=720 mg oral morphine/d) converted to

sublingual buprenorphine 3.2 mg/d (=32/90?mg oral morphine/d)

Pregabalin 450 mg/daily (reduced to 150 mg )

Diclofenac (Voltaren) 150 mg daily (discontinued)

Lanzoprazol 60 mg/daily (reduced to 15 mg/d)

Atorvastatin (Lipitor)40 mg/d (causes muscle pain--discontinued)

Amitriptylin 50 mg (anticholinergic and sedative--discontinued)

Enda et «interessant» tilfelle

# Loperamid (Immodium)

kept out of CNS by effluxtransporter Pgp

70 yrs patient with LBP and PPP (persistent pelvic pain)

On OxyContin 10 mg bid (+?) → OIGIDF

Complained of cardialgia → on a PPI

Complained of diarea (?) («**obstipasjons-diare**»)

Used Immodium several days/wk to stop «diarea»

This stopped «diarea» and relieved her LBP, but  
not her PersistentPelvicPain

On exam: Massive content in rectum, «full» colon

What to do?



**98 yrs** man with **severe claudicatio intermit**, and acute L2-3 **prolapsed disc** with radicular pain, reduced strength in thigh muscles of left leg: Rx.:  
paracetamol + oxycodone + prednisolon + **amitriptylin 10 mg (dizzy!)**.

He had been on dabigatran (**Pradaxa**) after a minor stroke a few years ago

eGFR<sub>creatinine</sub> about **50 ml/min** (he is not using his legs much)

eGFR<sub>cystatinC</sub> only **22 ml/min**

Dabigatran excreted by kidneys; is **contraindicated** if eGFR < 30 ml/min/1.7m<sup>2</sup>

**He fell**, hit the front of his skull and right shoulder → **profuse bleeding**

**Dabigatran** was changed to **apixaban (Eliquis)**

**Atorvastatin** (Lipitor) that causes muscle-pain was **discontinued** (LDL = 1.2)

**In small children and elderly (>75yrs): cystatin C in serum → correct estimates of renal function (eGFR)**

For his LBP: Prednisolon 20 mg → Tapered and DC I løpet av 14 dager.

# Alvorlige bivirkninger av antikolinerge medikament til eldre og gamle

# **AntiCholinergic** drugs cause unpleasant sedation; cognitive dysfunction; muscle-dysfunction; aggravate pain

## **Strong anticholinergic drugs**

Atropine

Scopolamine

**Alimemazine** (Valergan)

**Amitriptylin** (Sarotex)

Clozapin (Leponex)

Doksepin (Sinequan)

## **Moderate anticholinergic drugs**

Klorpromazine

**Nortriptylin** (Noritren)

Kvetiapin (Seroquel)

**Benzodiazepines**

**Z-hypnotica**

**All sedative antihistamines**

**Some opioids, e.g. fentanyl**

# The Burden of Anticholinergic drugs → increased risk of dementia

**Memory-loss; hallucinations; agitation; unclear; agitated; delirium**

**Sedation → "sleep" → not-refreshing sleep**

**Mydriasis (bella-donna), accommodation-paresis → unclear vision**

**Motoric restless → myoclonic twitching → misdiagnosed as "epileptic"**

**Cardiac effects: Tachyarrhythmia's**

**Xerostomia**

**Urinary retention**

**OBS: Increased risk of dementia**

(Gray SL, Hanlon JT. *BMJ* 2018;361:k1722)

# Anticholinergic drugs and increased risk of dementia in older adults

## Should we be concerned?

Gray SL, Hanlon JT. *BMJ* 2018;361:k1722 (Published 25 April 2018)

Anticholinergic drugs prevent acetylcholine from binding to muscarinic and nicotinic receptors, have numerous **adverse effects, especially in older adults.**

Anticholinergics, **used by 10-27% of older adults**, for overactive bladder, seasonal allergies, and depression.

They can cause temporary **impairment in cognition**, reduced attention and memory, longer reaction time.

Evidence now show that they **increase risk of dementia**, especially

- **anticholinergic antidepressants,**
- **antiparkinsonian drugs,**
- **drugs to treat urinary incontinence.**

Richardson K et al: Anticholinergic drugs and risk of dementia. *BMJ* 2018;361:k1315

Richardson K et al:

Anticholinergic drugs and risk of dementia; a case control study.

BMJ 2018;361:k1315

15 000 cases and 86 000 controls

### WHAT THIS STUDY ADDS

Antidepressant, urological, and antiparkinson drugs with definite anticholinergic activity are linked to future dementia incidence, with associations persisting up to 20 years after exposure

Gastrointestinal and cardiovascular anticholinergic drugs are not positively associated with later dementia incidence

**Amitriptylin (Sarotex) should **NOT** be prescribed for those > 65 + years**

→ **sedated, orthostatic, dizziness**

→ **risk of →fall**

**Elderly who fall → increased mortality**

(Nortriptylin a bit better?)

Dworkin et al. Pain 2007

**98 yrs** man with **severe claudicatio intermit**, and acute L2-3 **prolapsed disc** with radicular pain, reduced strength in thigh muscles of left leg: Rx.:  
paracetamol + oxycodone + prednisolon + **amitriptylin 10 mg (dizzy!)**.

He had been on dabigatran (**Pradaxa**) after a minor stroke a few years ago

eGFR<sub>creatinine</sub> about **50 ml/min** (he is not using his legs much)

eGFR<sub>cystatinC</sub> only **22 ml/min**

Dabigatran excreted by kidneys; is **contraindicated** if eGFR < 30 ml/min/1.7m<sup>2</sup>

**He fell**, hit the front of his skull and right shoulder → **profuse bleeding**

**Dabigatran** was changed to **apixaban (Eliquis)**

**Atorvastatin** (Lipitor) that causes muscle-pain was **discontinued** (LDL = 1.2)

**In small children and elderly (>75yrs): cystatin C in serum → correct estimates of renal function (eGFR)**



Viktigste «take home message»

# WHO(2015):Healthy aging – what can we do?

- Skaff deg en god utdanning
- Ikke røke tobakk
- Bruk svært lite alkohol
- Sunn livsstil senest fra 30-års alder
- Behandle høgt blodtrykk allerede i “middle age”
- Diet med fisk og grønnsaker (“Mediterranean diet”)
- **Vær fysisk aktiv, mentalt aktiv, og sosialt aktiv**
- Høre-apparat er viktig
- **Hold din partner sunn og glad.**
- **Keep your partner healthy and happy.**

Stor takk!